WASHINGTON - Vanda (NASDAQ:VNDA) Pharmaceuticals Inc. (NASDAQ: VNDA), a global biopharmaceutical company, has declined a second acquisition proposal from Cycle Group Holdings Ltd., maintaining that the $8.00 per share cash offer undervalues the company. The bid, which matches a previous offer made on May 24, 2024, was unanimously rejected by Vanda's Board of Directors after a thorough review, conducted with the aid of independent legal and financial advisors.
The Board reassessed Vanda's business, including its clinical development pipeline, market presence, and financial health, concluding that Cycle Group's proposal is an attempt to acquire the company at a price lower than its intrinsic value. Vanda's leadership remains confident in the company's growth trajectory and believes its strong cash position and operational efficiency will lead to significant long-term value for shareholders, surpassing the offer from Cycle Group.
Vanda advises its shareholders that no action is required from them at this juncture. The company continues to focus on the development and commercialization of novel therapies aimed at unmet medical needs and improving patient outcomes.
The press release from Vanda Pharmaceuticals also included forward-looking statements, cautioning that these are subject to risks, uncertainties, and changes in circumstances, and that there can be no certainty that the anticipated results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the company.
The information is based on a press release statement and reflects the company's position as of the date of the announcement. Vanda has stated it will not undertake any obligation to publicly update or revise any forward-looking statements.
In other recent news, Cycle Pharmaceuticals has proposed an acquisition of all outstanding shares of Vanda Pharmaceuticals for $8 per share, a total equity value of $488 million. The offer comes despite the FDA's recent rejection of Vanda's drug, tradipitant. Vanda has reported a net loss of $8.7 million for the first half of 2024, even with a 10% revenue increase in the second quarter compared to the previous year. The company's revenue guidance for 2024 is between $180 million and $210 million.
Vanda has also amended its bylaws and shareholder rights agreement, introducing changes to provide a clearer framework for identifying potential significant interest acquisitions in the company. These amendments follow the FDA's non-approval of their New Drug Application for tradipitant, a proposed treatment for gastroparesis. Vanda remains committed to pursuing the drug's approval and is also developing a new drug application for milsaperidone and initiating a clinical program for major depression.
In addition to these developments, Vanda has highlighted the FDA approval of Fanapt for bipolar I disorder and the expansion of its commercial organization. These are the recent developments for Vanda Pharmaceuticals.
InvestingPro Insights
Vanda Pharmaceuticals' rejection of Cycle Group's $8.00 per share offer aligns with several key financial metrics and insights from InvestingPro. According to InvestingPro data, Vanda's market capitalization stands at $292.61 million, significantly below the implied valuation of the rejected offer. This discrepancy suggests that the market may not fully reflect the company's intrinsic value, as perceived by Vanda's Board.
An InvestingPro Tip indicates that Vanda "holds more cash than debt on its balance sheet," which supports the company's assertion of a strong cash position. This financial stability likely contributes to the Board's confidence in rejecting the acquisition proposal and pursuing long-term value creation independently.
Another relevant InvestingPro Tip notes that "net income is expected to grow this year." This projection aligns with Vanda's optimistic outlook on its growth trajectory and potential to deliver shareholder value exceeding the current offer.
It's worth noting that InvestingPro provides 5 additional tips for Vanda Pharmaceuticals, offering investors a more comprehensive analysis of the company's financial health and prospects.
The InvestingPro Fair Value for Vanda is estimated at $6.11 per share, while the average analyst price target is $6.00. Both figures, while lower than the rejected offer, suggest potential upside from the current trading price, which closed at $4.44 in the most recent session. This valuation gap may indicate why Vanda's management believes the company is undervalued at the proposed acquisition price.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.